PURPOSE OF REVIEW: Idiopathic inflammatory myopathies (IIMs), known also as myositis, represent challenging group of heterogeneous muscle disorders characterized by symmetric proximal muscle weakness and evidence of muscle inflammation. The purpose of this review is to provide important updates on cytokines and inflammatory mediators related to myositis. RECENT FINDINGS: In the past 5 years, multiple studies brought a fresh insight into the pathogenesis of myositis by introducing new factors or further characterizing the role of the well established mediators in myositis. Among the mediators reviewed in this article, special attention was paid to interferons, C-X-C motif chemokine ligand 10, interleukin-18 and the IL23/Th17 axis. Some of the recent work has also focused on the nontraditional cytokines, such as adipokines, myokines, S100 proteins, High Mobility Group Box 1 or B-cell activating factor and on several anti-inflammatory mediators. Moreover, microRNAs and their potential to reflect the disease activity or to regulate the inflammatory processes in myositis have recently been subject of intensive investigation. Some of the above-mentioned mediators have been proposed as promising clinical biomarkers or therapeutic targets for myositis. SUMMARY: Several recent studies contributed to a better understanding of the pathogenesis of myositis and highlighted the clinical significance of certain inflammatory mediators. Application of these new findings may help to develop innovative approaches for patients' phenotyping, disease activity monitoring and potentially novel therapies.

Department of Rheumatology 1 Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology

See more in PubMed

Vencovský J, Alexanderson H, Lundberg IE. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2019; 45:569–581.

Kubínová K, Mann H, Vencovský J. MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2017; 29:623–631.

Ghirardello A, Doria A. New insights in myositis-specific autoantibodies. Curr Opin Rheumatol 2018; 30:614–622.

Gallay L, Mouchiroud G, Chazaud B. Interferon-signature in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2019; 31:634–642.

De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009; 21:610–616.

Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 2018; 141:1609–1621.

Moneta GM, Pires Marafon D, Marasco E, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol 2019; 71:1011–1021.

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology 2019; 93:e1193–e1204.

Rigolet M, Hou C, Baba Amer Y, et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. RMD Open 2019; 5:e000811.

Kim H, Gunter-Rahman F, McGrath JA, et al. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther 2020; 22:69.

Ivanidze J, Hoffmann R, Lochmüller H, et al. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers. Am J Pathol 2011; 179:1347–1359.

Raju R, Vasconcelos O, Granger R, Dalakas MC. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003; 141:125–131.

De Paepe B, De Keyzer K, Martin JJ, De Bleecker JL. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol 2005; 109:576–582.

Allenbach Y, Chaara W, Rosenzwajg M, et al. Th1 response and systemic Treg deficiency in inclusion body myositis. PLoS One 2014; 9:e88788.

Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 2014; 53:2196–2203.

Reed AM, Peterson E, Bilgic H, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012; 64:4078–4086.

Kim J, Choi JY, Park SH, et al. Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. Arthritis Res Ther 2014; 16:R126.

Chen M, Quan C, Diao L, et al. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Br J Dermatol 2018; 179:1334–1341.

Wienke J, Bellutti Enders F, Lim J, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation. Arthritis Rheumatol 2019; 71:1377–1390.

Nakanishi K. Unique action of interleukin-18 on T cells and other immune cells. Front Immunol 2018; 9:763.

Tucci M, Quatraro C, Dammacco F, Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006; 146:21–31.

Shen H, Xia L, Lu J. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases. Cytokine 2012; 60:334–337.

Gono T, Kawaguchi Y, Sugiura T, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford) 2010; 49:1878–1881.

Yang Y, Yin G, Hao J, et al. Serum interleukin-18 level is associated with disease activity and interstitial lung disease in patients with dermatomyositis. Arch Rheumatol 2017; 32:181–188.

Zou J, Chen J, Yan Q, et al. Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease. Clin Rheumatol 2016; 35:117–125.

Helmers SB, Bruton M, Loell I, et al. Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. Rheumatology (Oxford) 2018; 57:2149–2157.

Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 2014; 178:405–415.

Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004; 50:199–208.

Fujiyama T, Ito T, Ogawa N, et al. Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin Exp Immunol 2014; 177:110–120.

Yin Y, Li F, Shi J, et al. MiR-146a regulates inflammatory infiltration by macrophages in polymyositis/dermatomyositis by targeting TRAF6 and affecting IL-17/ICAM-1 pathway. Cell Physiol Biochem 2016; 40:486–498.

Notarnicola A, Lapadula G, Natuzzi D, et al. Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. Scand J Rheumatol 2015; 44:224–228.

Shen H, Xia L, Lu J, Xiao W. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 2011; 40:217–220.

Gupta L, Chaurasia S, Srivastava P, et al. Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults. Clin Rheumatol 2018; 37:1265–1271.

Silva MG, Oba-Shinjo SM, Marie SKN, Shinjo SK. Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 2019; 37:656–662.

Jin Y, Lin Y, Lin L, Zheng C. IL-17/IFN-γ interactions regulate intestinal inflammation in TNBS-induced acute colitis. J Interferon Cytokine Res 2012; 32:548–556.

Lee J, Lee J, Park MK, et al. Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2, 3-deoxygenase. PLoS One 2013; 8:e60900.

Liu T, Hou Y, Dai TJ, Yan CZ. Upregulation of interleukin 21 and interleukin 21 receptor in patients with dermatomyositis and polymyositis. Chin Med J (Engl) 2017; 130:2101–2106.

Kageyama T, Suto A, Iwamoto T, et al. IL-21 exacerbates autoimmune myositis by enhancing the accumulation of GM-CSF-producing γδ T cells in the muscle. ImmunoHorizons 2017; 1:176–187.

Wang K, Zhao J, Chen Z, et al. CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease (published correction appears in Rheumatology (Oxford). Rheumatology (Oxford) 2019; 58:511–521.

Tournadre A, Lenief V, Eljaafari A, Miossec P. Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 2012; 64:533–541.

Umezawa N, Kawahata K, Mizoguchi F, et al. Interleukin-23 as a therapeutic target for inflammatory myopathy. Sci Rep 2018; 8:5498.

Seeliger S, Vogl T, Engels IH, et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. Am J Pathol 2003; 163:947–956.

Nistala K, Varsani H, Wittkowski H, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther 2013; 15:R131.

Pleštilová L, Mann H, Andrés Cerezo L, et al. The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Res Ther 2014; 16:468.

Andrés Cerezo L, Hulejová H, Sumova B. Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. Cytokine 2019; 116:13–20.

Filková M, Hulejová H, Kuncová K, et al. Resistin in idiopathic inflammatory myopathies. Arthritis Res Ther 2012; 14:R111.

Olazagasti JM, Hein M, Crowson CS, et al. Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. J Inflamm (Lond) 2015; 12:29.

Hulejová H, Kryštůfková O, Mann H, et al. Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. Clin Exp Rheumatol 2016; 34:222–229.

Baek A, Park HJ, Na SJ, et al. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 2012; 249:96–100.

Krystufková O, Vallerskog T, Helmers SB, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009; 68:836–843.

Kryštůfková O, Barbasso Helmers S, Venalis P, et al. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther 2014; 16:454.

Xu LG, Wu M, Hu J, et al. Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 2002; 72:410–416.

Loaiza-Félix J, Moreno-Ramírez M, Pérez-García FL, et al. Serum levels of adipokines in patients with idiopathic inflammatory myopathies: a pilot study. Rheumatol Int 2017; 37:1341–1345.

Lightfoot AP, Cooper RG. The role of myokines in muscle health and disease. Curr Opin Rheumatol 2016; 28:661–666.

De Paepe B, Verhamme F, De Bleecker JL. The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis. Cytokine 2020; 127:154966.

Vernerová L, Horváthová V, Kropáčková T, et al. Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies. Rheumatology (Oxford) 2020; 59:2491–2501.

Zong M, Loell I, Lindroos E, et al. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2012; 71:1055–1063.

Sugiura T, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 2000; 164:6593–6600.

Sugiura T, Harigai M, Kawaguchi Y, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 2002; 14:917–924.

Ruck T, Bittner S, Afzali AM, et al. The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget 2015; 6:43230–43243.

Yan W, Fan W, Chen C, et al. IL-15 up-regulates the MMP-9 expression levels and induces inflammatory infiltration of macrophages in polymyositis through regulating the NF-kB pathway. Gene 2016; 591:137–147.

O’Leary MF, Wallace GR, Bennett AJ, et al. IL-15 promotes human myogenesis and mitigates the detrimental effects of TNFα on myotube development. Sci Rep 2017; 7:12997.

Ulfgren AK, Grundtman C, Borg K, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50:1586–1594.

Muth IE, Zschüntzsch J, Kleinschnitz K, et al. HMGB1 and RAGE in skeletal muscle inflammation: implications for protein accumulation in inclusion body myositis. Exp Neurol 2015; 271:189–197.

Grundtman C, Bruton J, Yamada T, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010; 24:570–578.

Zong M, Bruton JD, Grundtman C, et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 2013; 72:1390–1399.

Shu X, Peng Q, Lu X, Wang F. HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis/dermatomyositis with interstitial lung disease. PLoS One 2016; 11:e0161436.

Day J, Otto S, Cash K, et al. Aberrant expression of high mobility group box protein 1 in the idiopathic inflammatory myopathies. Front Cell Dev Biol 2020; 8:226.

Peng QL, Shu XM, Wang DX, et al. B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med 2014; 8:395–403.

Kobayashi N, Kobayashi I, Mori M, et al. Increased serum B-cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol 2015; 42:2412–2418.

Noda S, Koike H, Maeshima S, et al. Transforming growth factor-β signaling is upregulated in sporadic inclusion body myositis. Muscle Nerve 2017; 55:741–747.

Wu CY, Li L, Zhang LH. Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance. Eur J Med Res 2019; 24:12.

Giriş M, Durmuş H, Yetimler B, et al. Elevated IL-4 and IFN-γ levels in muscle tissue of patients with dermatomyositis. In Vivo (Brooklyn) 2017; 31:657–660.

Xu WD, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases. Autoimmun Rev 2015; 14:1170–1175.

Yan P, Zhang Y, Wang C, et al. Interleukin-37 (IL-37) suppresses pertussis toxin-induced inflammatory myopathy in a rat model. Med Sci Monit 2018; 24:9187–9195.

Parkes JE, Day PJ, Chinoy H, Lamb JA. The role of microRNAs in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2015; 27:608–615.

Shimada S, Jinnin M, Ogata A, et al. Serum miR-21 levels in patients with dermatomyositis. Clin Exp Rheumatol 2013; 31:161–162.

Yu L, Li J, Chen Y, et al. hsa-miR-7 is a potential biomarker for idiopathic inflammatory myopathies with interstitial lung disease in humans. Ann Clin Lab Sci 2018; 48:764–769.

Misunova M, Salinas-Riester G, Luthin S, et al. Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activity. Clin Exp Rheumatol 2016; 34:17–24.

Hirai T, Ikeda K, Tsushima H, et al. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen 2018; 38:1.

Ye L, Zuo Y, Yang H, et al. Specific autoantibodies and clinical phenotypes correlate with the aberrant expression of immune-related microRNAs in dermatomyositis. J Immunol Res 2019; 2019:2927061.

Georgantas RW, Streicher K, Greenberg SA, et al. Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. Arthritis Rheumatol 2014; 66:1022–1033.

Xu D, Huang CC, Kachaochana A, et al. MicroRNA-10a regulation of proinflammatory mediators: an important component of untreated juvenile dermatomyositis. J Rheumatol 2016; 43:161–168.

Yan W, Chen C, Chen H. Estrogen downregulates miR-21 expression and induces inflammatory infiltration of macrophages in polymyositis: role of CXCL10. Mol Neurobiol 2017; 54:1631–1641.

Liu Y, Gao Y, Yang J, et al. MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1. Int J Oncol 2018; 53:1332–1342.

Jiang T, Huang Y, Liu H, et al. Reduced miR-146a promotes REG3A expression and macrophage migration in polymyositis and dermatomyositis. Front Immunol 2020; 11:37.

Kinder TB, Heier CR, Tully CB, et al. Muscle weakness in myositis: microRNA-mediated dystrophin reduction in a myositis mouse model and human muscle biopsies. Arthritis Rheumatol 2020; 72:1170–1183.

Hsp90 as a Myokine: Its Association with Systemic Inflammation after Exercise Interventions in Patients with Myositis and Healthy Subjects

Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study

The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up